Article Figures & Data
Figures
- FIGURE 1.
Trial design. DLT = dose-limiting toxicities.
- FIGURE 2.
Subject 1. (A) 111In-pentetreotide axial SPECT image through mid liver demonstrating multiple octreopeptide-positive metastases with focal intense uptake in target lesion (arrow). (B) 131I-MIBG SPECT axial slice at same level demonstrating intense uptake in same lesion (arrow). (C) Corresponding baseline venous phase CT scan depicting multiple liver metastases consistent with SPECT findings. Target lesion is 35.5 mm in maximum diameter. (D) Follow-up CT 6-mo after cycle 2 showing measurement of target lesion (maximum diameter, 26.4 mm).
- FIGURE 3.
Modified trial design. AA = administered activity; DOTATE = DOTATATE; SOC = standard of care.
Tables
- TABLE 1
Calculated Administered Activity Levels to Achieve Dose Limit of 1,900 cGy to Kidneys Plus 150 cGy to Bone Marrow
Maximum total activity 90Y-DOTATOC plus 131I-MIBG (GBq) Subject no. Maximum total activity 90Y-DOTATOC only (GBq) 90Y-DOTATOC 131I-MIBG 1 10.8 8.7 11.4 2 7.8 5.6 18.3 3 5.0 2.8 18.7 Cycle 1 Cycle 2 Parameter Baseline 1 mo 2 mo 1 mo 2 mo 6 mo Creatinine (mg/dL) Subject 1 1.20 1.1 1.10 1.30 1.10 1.60 Subject 2 1.10 0.86 0.94 0.98 1.13 1.00 Subject 3 1.10 1.14 0.95 1.00 1.07 1.10 Platelet (k/mm3) Subject 1 396 151 215 191 216 165 Subject 2 187 82 128 86 130 189 Subject 3 253 107 150 111 47 173 Absolute neutrophil count (cells/mm3) Subject 1 5,050 6,510 4,310 5,630 4,560 4,100 Subject 2 6,510 4,500 3,800 4,100 4,800 5,180 Subject 3 3,230 3,393 1,575 3,281 1,332 3,520
